Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Ustekinumab Cingoz OMAbs 2009[May]; 1 (3): 216-21Ustekinumab is an anti-IL12/23 IgG1 kappa human monoclonal antibody currently undergoing US Food and Drug Administration review for use as a psoriasis treatment. The candidate has also been evaluated in Phase 2 studies as a treatment for psoriatic arthritis, Crohn disease and multiple sclerosis.In large clinical trials, ustekinumab has proven effective for treating moderate to severe plaque psoriasis. Although long-term follow-up studies are needed to address safety concerns, the hopes are high for psoriasis treatment. Ustekinumab has recently been approved for marketing in Canada and Europe.|Animals[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/adverse effects/*therapeutic use[MESH]|Arthritis, Psoriatic/*drug therapy/immunology[MESH]|Canada[MESH]|Clinical Trials as Topic[MESH]|Crohn Disease/*drug therapy/immunology[MESH]|Drug Approval[MESH]|Europe[MESH]|Humans[MESH]|I-kappa B Proteins/immunology[MESH]|NF-KappaB Inhibitor alpha[MESH]|NF-kappa B/antagonists & inhibitors[MESH]|United States[MESH]|Ustekinumab[MESH] |
